ORASIS PHARMACEUTICALS
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, and easy-to-use.
ORASIS PHARMACEUTICALS
Industry:
Clinical Trials Health Care Medical Pharmaceutical
Founded:
2015-01-01
Address:
Herzliya, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.orasis-pharma.com
Total Employee:
1+
Status:
Active
Contact:
+972-9-8877745
Email Addresses:
[email protected]
Total Funding:
43 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Euro Cloudflare JS CDN JS W3 Total Cache
Current Advisors List
Current Employees Featured
Founder
Investors List
Sequoia Capital
Sequoia Capital investment in Series C - Orasis Pharmaceuticals
LifeSci Venture Partners
LifeSci Venture Partners investment in Series C - Orasis Pharmaceuticals
Bluestem Capital
Bluestem Capital investment in Series C - Orasis Pharmaceuticals
Visionary Venture Fund
Visionary Venture Fund investment in Series C - Orasis Pharmaceuticals
SBI Japan-Israel Innovation Fund
SBI Japan-Israel Innovation Fund investment in Series C - Orasis Pharmaceuticals
Maverick Ventures
Maverick Ventures investment in Series C - Orasis Pharmaceuticals
Sequoia Capital
Sequoia Capital investment in Series B - Orasis Pharmaceuticals
Visionary Venture Fund
Visionary Venture Fund investment in Series B - Orasis Pharmaceuticals
SBI Japan-Israel Innovation Fund
SBI Japan-Israel Innovation Fund investment in Series B - Orasis Pharmaceuticals
LifeSci Venture Partners
LifeSci Venture Partners investment in Series B - Orasis Pharmaceuticals
Official Site Inspections
http://www.orasis-pharma.com Semrush global rank: 3.1 M Semrush visits lastest month: 5.19 K
- Host name: 50.190.174.34.bc.googleusercontent.com
- IP address: 34.174.190.50
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Orasis Pharmaceuticals"
Orasis Pharmaceuticals - Org Chart, Teams, Culture & Jobs - The Org
View Orasis Pharmaceuticals' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Org Chart Orasis Pharmaceuticals - The Official Board
The organizational chart of Orasis Pharmaceuticals displays its 15 main executives including Elad Kedar, Paul Smith and Ron Neumann ... www.orasis-pharma.com. has 15 executives +972 …See details»
Orasis Pharmaceuticals: Contact Details and Business Profile
Orasis-pharma.com; 5+ 714213XXXX; 714579XXXX; 949466XXXX; 949297XXXX; 917865XXXX; 917885XXXX; Julia Reznick VP Finance and Business Development at Orasis …See details»
Orasis Pharmaceuticals Company Profile 2024: Valuation, Funding ...
Www.orasis-pharma.com. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. 101 Marketside Avenue; Suite 404-324; Ponte Vedra …See details»
Orasis Pharmaceuticals - Crunchbase Company Profile …
Contact Email [email protected]; Phone Number +972-9-8877745 ; Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for …See details»
Orasis Pharmaceuticals' CEO and Executive Team - The Org
The executive team at Orasis Pharmaceuticals has a history in general management, marketing, finance, technology sales, and ocular drug development. They have experience working for …See details»
Orasis Pharmaceuticals Ltd. - Drug pipelines, Patents ... - Patsnap
Explore Orasis Pharmaceuticals Ltd. with its drug pipeline, therapeutic area, technology platform, 7 clinical trials, 11 news, and 1 literature, Technology Platform:Small molecule drug, …See details»
Orasis Pharmaceuticals Appoints Industry Veteran, Paul Smith, as ...
HERZLIYA, Israel, April 26, 2021 – Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the …See details»
Orasis Pharmaceuticals - Company Profile - Tracxn
Nov 8, 2024 Orasis Pharmaceuticals ranks 16th among 204 active competitors. 70 of its competitors are funded while 57 have exited. Overall, Orasis Pharmaceuticals and its …See details»
Company Overview - Orasis - orasis-pharma.com
WE INVITE CONSTRUCTIVE DISRUPTION. …to challenge the status quo. …to push the benchmarks of success. Because we see a way to a better future and a better self through reshaping vision possibilities. Orasis is an emerging …See details»
Orasis Pharmaceuticals - Overview, News & Similar companies
Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia - Phase 3 NEAR-1 and NEAR-2 clinical …See details»
Orasis Company Profile - Office Locations, Competitors, Revenue …
Orasis has 5 employees at their 1 location and $43 m in total funding,. See insights on Orasis including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Orasis Pharmaceuticals Strengthens Leadership Team with Key …
Ponte Vedra, FL, October 14, 2024 – Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on reshaping vision possibilities, today announced the …See details»
Israeli Startup Orasis Pharmaceuticals Develops Innovative …
Oct 11, 2024 Orasis Pharmaceuticals is an Israeli startup and an emerging ophthalmic pharmaceutical company focused on reshaping vision possibilities. The company deals …See details»
Orasis Pharmaceuticals Company Profile, Investors, & Funding
WE INVITE CONSTRUCTIVE DISRUPTION. Orasis is an emerging ophthalmic pharmaceutical company with an FDA approved prescription eye drop, QLOSI™ (pilocarpine HCl ophthalmic …See details»
Orasis Pharmaceuticals Strengthens Leadership Team
Oct 14, 2024 [email protected] 412-327-9499. References: 1 Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%. Prescribing Information. Orasis …See details»
Orasis Pharmaceuticals (Israel) Funding: $126M - Medical Startups
Nov 26, 2024 Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia as an alternative to reading...See details»
Orasis Pharmaceuticals Completes $78 Million Financing to …
Oct 8, 2024 $68 Million Series D Financing Co-led by Arboretum Ventures and Johnson & Johnson Innovation – JJDC, Inc. Secured $15 Million in Structured Capital from Catalio Capital …See details»
Ionis has much riding on drug approval and major strategic shift
Dec 13, 2024 This isn’t just a drug approval, but a major strategic shift. For more than 30 years, Ionis developed all of its medicines in partnership with large pharmaceutical companies.See details»
Investors - Orasis - orasis-pharma.com
Orasis is funded by a diverse group of sophisticated investors with proven track records in the healthcare space. In October 2024, Orasis announced a Series D financing co-led by …See details»